Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
a study on Cancer, General Anal Cancer Colorectal Cancer Biliary Tract Cancer Cholangiocarcinoma Neuroendocrine Tumor Carcinoid Tumor Endometrial Cancer Cervical Cancer Vulvar Carcinoma Vulvar Cancer Lung Cancer Mesothelioma Thyroid Cancer Salivary Gland Carcinoma Salivary Gland Cancer Salivary Cancer Parotid Gland Cancer Solid Tumor Carcinoma Neoplasms Colorectal Tumor
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma, Programmed Cell Death-1 (PD1, PD-1), Programmed Death-Ligand 1 (PDL1, PD-L1), microsatellite instability (MSI), mismatch repair (MMR), Carcinoma, Neoplasms, Endometrial Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Colorectal Neoplasms, Salivary Gland Neoplasms, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases, Pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab 400 mg
Lead Scientist at University of California Health
- Emily Bergsland (ucsf)
Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center.